Senores Pharmaceuticals Ltd News
Senores Pharma to acquire 14 ANDAs from Dr Reddy's for US markets
Gujarat-based Senores Pharmaceuticals on Tuesday said it will acquire a basket of 14 Abbreviated New Drug Applications from Dr Reddy's Laboratories for an undisclosed amount. Senores Pharmaceuticals, Inc, USA, a subsidiary of the drug firm, has inked agreements with Dr Reddy's for acquiring the Abbreviated New Drug Applications (ANDAs), the company said in a statement. The basket includes 13 ANDAs approved by the USFDA (US Food and Drug Administration), with one application pending approval, it added. The addressable opportunity of the acquired ANDAs in the US is around USD 421 million as per IQVIA. Senores said the acquisition will be funded through the initial public offer proceeds. This is in line with the objects of the IPO stated in the Red Herring Prospectus, it added. Senores Pharmaceuticals MD Swapnil Shah said the acquired molecules span multiple therapeutic areas with growing consumption. The portfolio consists of controlled substances and the general category of produ
Senores Pharma up 7% on acquiring 14 ANDAs from Dr. Reddy's Laboratories
The basket acquired, comprises of 13 ANDAs, which are approved by the US Food anf Drugs Administration (US FDA) and 1 ANDA, which is pending approval from the USFDA
Senores Pharma rises 6% after its arm inks agreement to acquire Roflumilast
Roflumilast is used for treatment to reduce the risk of Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis
Senores Pharmaceuticals races 17% on robust Q3; profit more than doubles
The rise in Senores Pharmaceuticals share came after the company's strong show in the December quarter (Q3FY25) results
Senores gains 43% on stock market debut; Ventive up 10%, Carraro dips 10%
The listing day performance was largely in line with the subscription levels for the threen IPOs
Senores Pharma IPO listing jackpot: Shares debut at bumper 52% premium
Senores Pharma shares listed at Rs 593.70 apiece on the BSE, reflecting a premium of 51.84 per cent over the IPO allotment price of Rs 391
